ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.
Tumour Sites: Genitourinary Cancers
Genitourinary Tract Tumours
Clinical Practice Guidelines
Latest ESMO videos
Featured medwireNews
MRI-Guided Prostate Biopsy Strategy Reduces Testing, Avoids Clinically Insignificant Cancer Diagnoses
KEYNOTE-564 Demonstrates DFS Benefit Of Adjuvant Pembrolizumab In High-Risk RCC
Pembrolizumab Monotherapy Promising For BCG-Unresponsive NMIBC
Immunotherapy-Based Regimens Show Real-World Metastatic Clear Cell RCC Survival Benefit
First-Line Nivolumab–Cabozantinib Boosts Advanced RCC Outcomes
E-Learning
ESMO E-Learning: Implications of Genomic and Genetic Testing for the Management of Prostate Cancer Patients
ESMO E-Learning: Management of Hormone-Sensitive Prostate Cancer
ESMO E-Learning: Metastatic Urothelial Carcinoma Systemic Second-Line Therapy: The Platinum-Refractory Setting
ESMO E-Learning: Sexuality and Intimacy after Cancer
ESMO E-Learning: Advances in Systemic Treatment of Advanced/Metastatic Renal Cell Carcinoma
Factsheets on Biomarkers
PD-L1 in Cancer: ESMO Biomarker Factsheet
Meeting resources
CN49 - A rapid review of patient reported outcomes for patients with renal cell cancer or hepatocellular cancer on treatment with targeted therapies
Presenter: Celia Díez de los Ríos de la Serna
Session: Supportive care and symptom management (EONS-MASCC)
Resources:
Abstract
1564MO - Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers
Presenter: Sabrina Salgia
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Abstract
516MO - Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
Presenter: Haeseong Park
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
579MO - CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
578MO - Phase Ib/II study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent (ARTA)
Presenter: Mark Markowski
Session: Mini oral session - Genitourinary tumours, prostate
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.